TY  - JOUR
T1  - EXperience is a gloomy lantern that does not even illuminate its bearer
AU  - Braillon A
Y1  - 2012/02/13
N1  - 10.1001/archinternmed.2011.760
JO  - Archives of Internal Medicine
SP  - 294
EP  - 294
VL  - 172
IS  - 3
N2  - 
Steinman1 stressed that millions of people were early adopters of rofecoxib (Vioxx; Merck Co) and rosiglitazone (Avandia; GlaxoSmithKline), which were withdrawn or restricted for severe safety concerns. Accordingly, the findings of Schwartz and Woloshin2 are very surprising. They showed evidence that a substantial proportion of the public mistakenly believes that the Food and Drug Administration approves only extremely effective drugs and drugs lacking serious adverse effects.2 This deserves 2 questions.

SN  - 0003-9926
M3  - doi: 10.1001/archinternmed.2011.760
UR  - http://dx.doi.org/10.1001/archinternmed.2011.760
ER  -